Cipla Q2 profit jumps 25% YoY to Rs 471 crore, beats Street estimates

Drug major Cipla on Wednesday posted 25 per cent year-on-year rise in consolidated profit at Rs 471.35 crore for the quarter ended September 30. The pharma major had posted a profit of Rs 377.05 crore in the corresponding quarter last year.

Analysts in an ETNow poll had projected a profit of Rs 404 crore.

Revenue increased 8 per cent to Rs 4,264.24 crore against Rs 3,947.93 crore in the same period last year.


Umang Vohra, MD and Global CEO, Cipla said, “Our home markets continued to bode well. India business recorded robust performance in trade generics and across all key therapies in branded business while in South Africa, the private market business outpaced the market significantly.”

Ebitda increased 21 per cent to Rs 909 crore in the September quarter.

Shares of Cipla were trading 2.79 per cent up at Rs 480.65 after the announcement of corporate results, while the Nifty reclaimed the psychologically important 12,000 mark for the first time since June 11.

R&D investment stood at Rs 295 crore, or 7 per cent of sales, during the quarter.

“South Africa private business delivers growth of 13 per cent on a year-on-year basis in local currency. US business delivers $135 million to grow at 25 per cent,” the company said.